Inhibikase Therapeutics Inc (IKT) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $2.09
• Market Cap: $119.23M
• EPS: $-0.04
• 52-Week High: $2.58
• 52-Week Low: $1.33

Market Sentiment

Inhibikase Therapeutics Inc currently has a Bullish sentiment score of 0.46.

About Inhibikase Therapeutics Inc

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Atlanta, Georgia, dedicated to advancing innovative therapies for Parkinson's disease (PD) and related neurodegenerative disorders. The company employs a novel dual-targeting approach that addresses both central and peripheral mechanisms of neurodegeneration, aiming to tackle significant unmet medical needs within the PD patient population. With a robust pipeline of therapeutics currently in clinical dev...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Inhibikase Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does IKT pay dividends?

Inhibikase Therapeutics Inc (IKT) does not currently pay a regular dividend.

What is IKT's market cap?

Inhibikase Therapeutics Inc (IKT) has a market capitalization of $119.23M with a current stock price of $2.09.